When Standard Oncology Runs Out of Options,
Find the Next Evidence-Based Pathway
Independent international tumor board review. Access to advanced cell therapies, bispecifics, ADCs, and clinical trials across 8 countries. Peer-reviewed treatment recommendations with PubMed-cited evidence. Global referral coordination — all free for referring physicians.
Which Patients Benefit Most?
Not every patient needs international oncology intelligence. But when standard pathways are exhausted, a structured global review may identify options that local searches cannot.
Three Clinical Decision Support Services
Outputs, not features. Each service produces a structured, actionable result for your patient.
Treatment Pathway Navigation
When local guidelines have been exhausted, we map the patient's molecular profile, prior treatments, and clinical status to available therapies and institutions across our global network.
- Matches patient cases to available institutions and therapies
- Identifies country-specific treatment access conditions
- Provides transparent cost estimates from multiple centers
- Coordinates travel, visa, and accommodation logistics
- Maintains referring physician oversight throughout
International Tumor Board
Submit de-identified cases for evaluation by 2–3 independent specialist oncologists. Receive a structured, consensus-based recommendation with PubMed citations within 48–72 hours.
- 2–3 independent specialist opinions per case
- Reduced bias through consensus methodology
- Structured case-based recommendation document
- Clinical trial eligibility assessment included
- Multi-country treatment landscape view
- Optional physician-to-physician consultation
Global Trial Intelligence
Access real-time intelligence on clinical trial availability across our network. We check feasibility, eligibility, and enrollment conditions — including one of the world's largest CAR-T trial ecosystems.
- 700+ CAR-T trials in China alone
- Trials across 8 countries
- Eligibility criteria matching against patient profile
- Real-time slot availability verification
- Next-generation therapy options (dual-target CAR-T, allogeneic)
- Enrollment coordination and logistics support
Areas of Highest Expertise
Strategic focus areas where our network has the deepest intelligence, trial density, and institutional experience.
Therapeutic Modalities
- CAR-T Cell Therapy (CD19, BCMA, CD22, dual-target)
- Bispecific Antibodies (CD3/CD20, BCMA/CD3)
- TIL (Tumor-Infiltrating Lymphocyte) Therapy
- Gamma Delta T-Cell Therapy
- NK (Natural Killer) Cell Therapy
- Antibody-Drug Conjugates (ADCs)
- Checkpoint Inhibitors & Combinations
- Personalized Cancer Vaccines
Rare & Emerging Targets
- GPC3 (Hepatocellular Carcinoma)
- Claudin18.2 (Gastric, Pancreatic)
- Mesothelin (Mesothelioma, Ovarian)
- GD2 (Neuroblastoma, Sarcoma)
- EGFRvIII (Glioblastoma)
- MUC1, MUC16 (Ovarian, Pancreatic)
- NY-ESO-1 (Sarcoma, Melanoma)
- MAGE-A4 (Multiple Solid Tumors)
Cancer Types
- DLBCL, ALL, AML, Multiple Myeloma
- Mantle Cell Lymphoma, Follicular Lymphoma
- Lung Cancer (NSCLC & SCLC)
- Pancreatic Cancer
- Gastric / Gastroesophageal Cancer
- Liver Cancer (HCC)
- Colorectal Cancer
- Glioblastoma
- Triple-Negative Breast Cancer
- Sarcoma & Rare Solid Tumors
Why Physicians Use CancerCareE Instead of Google
Literature searches identify papers. They do not produce clinical pathways. CancerCareE bridges the gap between published evidence and actionable international treatment coordination.
Google / PubMed
CancerCareE
Intelligence You Cannot Easily Collect Yourself
Beyond published response rates — the real-world data that shapes treatment access decisions.
Practical Intelligence for Clinical Decision-Making
- Real-World Outcome Data: Aggregated, anonymized response rates, PFS, and adverse event profiles from partner institutions — where available.
- Waiting Time & Manufacturing Slots: Actual vein-to-vein timelines for CAR-T and cell therapy manufacturing across multiple centers and countries.
- Country-Specific Availability: Which therapies and trials are accessible in which countries — and under what regulatory and administrative conditions.
- Travel & Logistics Feasibility: Visa requirements, medical visa processing timelines, accommodation options, and language support availability.
- Hospital & Program Experience: Volume and experience data for specific therapies at specific institutions — information not published in journals.
- Trial Slot Availability: Real-time verification of enrollment slots — not just trial listings, but actual open positions.
Availability of specific data points varies by institution, country, and clinical study. All data shared is de-identified and aggregated.
Case Stories
Real examples of how international oncology intelligence identified pathways that were not visible through local search.
Relapsed DLBCL After Second-Line Therapy
52-year-old male, refractory to R-CHOP and R-ICE
Prior Therapies: R-CHOP ×6, R-ICE ×3 — progressive disease after each. Not eligible for local CAR-T due to manufacturing slot unavailability.
Molecular Finding: CD19-positive, confirmed by flow cytometry. Adequate organ function.
Review Outcome: International tumor board recommended dual-target CD19/CD22 CAR-T study with available enrollment slot in China.
Selected Center: Academic medical center, Shanghai — active CAR-T program with 14-day vein-to-vein time.
Treatment path: Lymphodepletion → dual-target CAR-T infusion. CR achieved at Day 28. MRD-negative at 6-month follow-up. Patient returned to home country for ongoing surveillance.
Advanced HCC with GPC3 Expression
64-year-old female, progressed on sorafenib and lenvatinib
Prior Therapies: Sorafenib → progression at 4 months. Lenvatinib → progression at 6 months. No local surgical or interventional options remaining.
Molecular Finding: GPC3-positive by IHC. Child-Pugh A. ECOG 1.
Review Outcome: Tumor board identified GPC3-targeted CAR-T phase I/II study with enrolling cohort. Confirmed eligibility within 72 hours.
Selected Country: China — GPC3 CAR-T trial not available in patient's home country.
Enrollment completed within 10 days. Stable disease at first assessment. Treatment ongoing at time of report.
Metastatic Gastric Cancer — CLDN18.2 Positive
58-year-old male, CLDN18.2 positive, third-line setting
Prior Therapies: FOLFOX → progression. Ramucirumab + paclitaxel → progression. No further local standard options.
Molecular Finding: Claudin18.2 expression confirmed (IHC 2+, >70% tumor cells). HER2-negative. MSI-stable.
Review Outcome: Tumor board recommended Claudin18.2-targeted CAR-T clinical study with active enrollment.
Selected Center: Cancer hospital, Beijing — one of the world's most experienced centers in CLDN18.2 CAR-T.
Referral coordinated within 5 days. Patient received CLDN18.2 CAR-T infusion. PR at Day 28 with significant symptomatic improvement.
Why China Matters in Global Oncology Intelligence
A strategic, evidence-based perspective — not a promotion. Understanding the Chinese oncology ecosystem helps physicians identify options that may not exist elsewhere.
🔬 World's Largest CAR-T Trial Ecosystem
Over 700 active CAR-T clinical trials — the largest concentration globally. This creates access opportunities for patients who cannot find trial slots or manufacturing capacity in other regions.
⚡ Fast Manufacturing & Vein-to-Vein Time
Chinese CAR-T programs often achieve vein-to-vein times of 14–21 days, compared with 4–8 weeks in some Western programs. For aggressive malignancies, this speed can be clinically meaningful.
🧬 Dual-Target & Next-Generation CAR-T Development
Chinese academic and commercial programs are actively developing dual-target (CD19/CD22, CD19/BCMA) and "armored" CAR-T constructs designed to reduce antigen escape — one of the leading causes of CAR-T failure.
🎯 Early Access to Novel Solid Tumor Targets
China has active solid tumor CAR-T programs targeting GPC3 (liver), Claudin18.2 (gastric/pancreatic), Mesothelin, and other targets that have limited or no trial availability in other countries.
🏥 High-Volume Centers with Therapy-Specific Experience
Several Chinese academic centers have treated hundreds of patients with specific CAR-T products — generating real-world experience data that is not yet captured in published literature.
⚖️ Regulatory & Quality Framework
China's NMPA (National Medical Products Administration) operates under ICH-GCP guidelines. Approved CAR-T products in China meet international manufacturing and clinical standards. Many trials are registered on ClinicalTrials.gov.
Security & Data Protection
Enterprise-grade security for clinical data — because trust is earned through protection, not promises.
End-to-End Encryption
256-bit SSL. Files encrypted at rest and in transit.
De-Identified Submissions
No PII shared without explicit consent.
Role-Based Access
MFA required. Only authorized personnel can view cases.
Complete Audit Trails
All access logged and auditable.
HIPAA-Aligned & GDPR-Ready
BAA available. European data protection compliant.
PHI Not Stored Longer Than Necessary
Secure deletion after case closure per data retention policy.
How Is This Service Funded?
CancerCareE does not charge physicians for treatment pathway review, international tumor board consultations, or trial intelligence services. All services are free for referring physicians and their patients.
Our network is sustained through institutional partnerships with hospitals. In some cases, partner institutions may compensate CancerCareE for administrative and coordination services. Clinical recommendations are developed independently and are not influenced by financial arrangements.
Who Can Access the Network?
Verification ensures quality and security for all participants in the clinical review process.
Eligible Physicians
- Board-certified oncologists (medical, radiation, surgical)
- Board-certified hematologists
- Active, unrestricted medical license
- Verified institutional affiliation
- Specialists in cellular therapy or immunotherapy
- Physicians treating rare or complex cancers
- Academic researchers in oncology
- Clinical trial investigators
Not Eligible
- Non-licensed practitioners
- Physicians with restricted or suspended licenses
- Alternative medicine providers without oncology certification
- Unverified institutional affiliations
- Commercial entities seeking patient data
- Individuals misrepresenting credentials
How to Get Started
Four steps from case submission to treatment pathway recommendation.
Submit Credentials
Complete the physician verification form with your license information and institutional affiliation.
Verification
We validate your medical license, board certification, and affiliation — typically within 24-48 hours.
Submit Patient Case
Upload de-identified case information for tumor board review and/or treatment pathway navigation.
Receive Recommendation
Structured, evidence-based pathway recommendation delivered within 48-72 hours.
Global Network
200+ partner institutions across 8 countries — academic medical centers, cancer hospitals, and clinical trial sites.
China
India
Turkey
South Korea
USA
Germany
Singapore
Frequently Asked Questions
CancerCareE provides three integrated clinical services: independent international tumor board review by 2-3 specialists, global clinical trial matching across 700+ CAR-T trials, and treatment pathway coordination at 200+ partner institutions. The goal is to produce a structured, evidence-based recommendation for next-step treatment options — not just a list of papers or trials.
CancerCareE is sustained through institutional partnerships with hospitals and administrative coordination fees from partner institutions. Clinical recommendations are developed independently. Referring physicians and their patients are never charged any fees.
Literature searches identify published data. CancerCareE adds real-world intelligence: actual waiting times for manufacturing slots, country-specific regulatory access conditions, hospital-specific experience volumes, travel feasibility assessments, and real-time trial slot availability. This information is not retrievable from PubMed or Google Scholar.
We use HIPAA-aligned security protocols including end-to-end encryption, de-identification of patient data, secure document upload, role-based access controls with MFA, and complete audit trails. PHI is not stored longer than necessary. GDPR compliance is maintained for European patients.
CancerCareE is an oncology intelligence and coordination layer — not a healthcare provider. We do not diagnose, treat, or prescribe. We provide clinical decision support through tumor board review, trial intelligence, and treatment pathway navigation. All medical decisions remain with the treating physician.
Request an Evidence-Based Pathway Review
Submit a de-identified case. Our international tumor board reviews your patient's molecular profile, prior treatments, and clinical status to identify actionable next-step pathways.
- Estimated eligibility
- Possible treatment pathways
- Relevant hospitals or centers
- Expected response range
- Next-step options if first-line treatment fails
HIPAA-aligned security • Free for physicians • 48-72h tumor board response